Glucocorticoid-Induced Osteoporosis

Adler, Robert A.; Weinstein, Robert S.

doi:10.1016/b978-0-12-415853-5.00049-2

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2017

2022

Publication Types

Select...

Article4

Other1

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 5 publications

(1 citation statement)

References 291 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Globally, 5–62% of the population on chronic glucocorticoid therapy in the USA, Canada, Europe and Latin America were also concomitantly prescribed with anti‐osteoporosis therapy . Additionally, an increasing rate of anti‐osteoporosis prophylaxis was noted in the USA .…”

Section: Introductionmentioning

confidence: 99%

Cost‐effectiveness of bisphosphonates for prevention of fracture related to glucocorticoid‐induced osteoporosis in Malaysia

et al. 2017

View full text Add to dashboard Cite

Fracture risk factors of age, previous fracture, rheumatoid arthritis and secondary osteoporosis may modify the cost-effectiveness outcomes of bisphosphonates. Bisphosphonates would be considered cost-effective in patients more than 60 years old as compared to calcium/vitamin D treatments. Further evaluation of the impact of fracture risk factors in larger populations would provide more precise information to better assist rational and economical use of anti-osteoporosis treatment in GIOP patients.

show abstract

Section: Introductionmentioning

confidence: 99%